Successful AstraZeneca lupus study bodes well for ImmuPharma’s Lupuzor™ – Sept 2019

13th September 2019 - 3:16 pm

Dr Navid Malik, Head of Life Sciences Research, tells Proactive London’s Andrew Scott the recent positive update for AstraZeneca‘s lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly successful product.

Share this article